Shingles, caused by the reactivation of the varicella zoster virus (VZV) that lies dormant after a primary chickenpox infection, affects a substantial share of the adult population over 50. Incidence rates in this age group range from approximately 5 to 11 new cases per 1,000 person-years depending on the region, and the condition tends to become both more frequent and more severe with age. Beyond the characteristic painful rash, roughly 5 to 30% of patients develop postherpetic neuralgia, a persistent nerve pain that can last for months and significantly impair quality of life. More recent evidence has also linked shingles infection to elevated stroke risk and higher rates of dementia, broadening the public health stakes of the disease.
It is in this context that Eli Lilly announced on May 26, 2026 its entry into a definitive agreement to acquire Curevo Vaccine, a Seattle-based clinical-stage biotechnology company developing next-generation VZV vaccines.
Curevo’s lead candidate, amezosvatein, is an adjuvanted subunit vaccine for shingles prevention that is currently Phase 3-ready. In a Phase 2 head-to-head trial against the current standard of care, the vaccine matched immune response across all primary endpoints while reducing side effects such as fatigue, chills, and injection site pain by more than half. The tolerability profile is the central commercial thesis: second-dose hesitancy and lower-than-expected uptake rates remain persistent issues with existing shingles vaccines, and a better-tolerated alternative could meaningfully expand coverage at the population level.
Under the terms of the agreement, Curevo shareholders could receive up to $1.5 billion in cash, consisting of an upfront payment and a milestone-contingent subsequent payment. The transaction remains subject to customary regulatory conditions, including Hart-Scott-Rodino antitrust clearance.
Centerview Partners and J.P. Morgan Securities advised Curevo on the financial side, with Cooley LLP acting as legal counsel.
van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021 Jun 3;17(6):1714-1732. doi: 10.1080/21645515.2020.1847582. Epub 2021 Mar 2. PMID: 33651654; PMCID: PMC8115759.